Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
The Phase 2 grant is for work the company is doing to analyze the proteomic responses of immune cells in patients with Alzheimer's and related conditions.
In PLOS this week: transcriptomics-based strategy to study Alzheimer's disease heterogeneity, insecticide resistance diversity and evolution, and more.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The study also found that certain genes may influence multiple complex traits, while others only affect one phenotype, making them worthwhile therapeutic targets.
